• SPX
  • 6090.27
  • 0.25 %
  • 15.1602
  • DJI
  • 44642.52
  • -0.28 %
  • -123.1914
  • N225
  • 39091.17
  • -0.77 %
  • -304.4297
  • FTSE
  • 8308.61
  • -0.49 %
  • -40.7695
  • IXIC
  • 19859.773
  • 0.81 %
  • 159.0508
Inhibikase Therapeutics, Inc. (IKT) Stock Price, News & Analysis

Inhibikase Therapeutics, Inc. (IKT) Stock Price, News & Analysis

Currency in USD Disclaimer

$3.28

$0.55

(20.15%)

Day's range
$2.68
Day's range
$3.33
50-day range
$1.13
Day's range
$3.69
  • Country: US
  • ISIN: US45719W2052
52 wk range
$1.12
Day's range
$3.82
  • CEO: Dr. Milton H. Werner Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -14.70
  • Piotroski Score 1.00
  • Grade Buy
  • Symbol (IKT)
  • Company Inhibikase Therapeutics, Inc.
  • Price $3.28
  • Changes Percentage (20.15%)
  • Change $0.55
  • Day Low $2.68
  • Day High $3.33
  • Year High $3.82

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/25/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $6.50
  • High Stock Price Target $8.00
  • Low Stock Price Target $5.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.32
  • Trailing P/E Ratio -0.51
  • Forward P/E Ratio -0.51
  • P/E Growth -0.51
  • Net Income $-19,028,883

Income Statement

Quarterly

Annual

Latest News of IKT

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Inhibikase Therapeutics, Inc. Frequently Asked Questions

  • What is the Inhibikase Therapeutics, Inc. stock price today?

    Today's price of Inhibikase Therapeutics, Inc. is $3.28 — it has increased by +20.15% in the past 24 hours. Watch Inhibikase Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Inhibikase Therapeutics, Inc. release reports?

    Yes, you can track Inhibikase Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Inhibikase Therapeutics, Inc. stock forecast?

    Watch the Inhibikase Therapeutics, Inc. chart and read a more detailed Inhibikase Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Inhibikase Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Inhibikase Therapeutics, Inc. stock ticker.

  • How to buy Inhibikase Therapeutics, Inc. stocks?

    Like other stocks, IKT shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Inhibikase Therapeutics, Inc.'s EBITDA?

    Inhibikase Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Inhibikase Therapeutics, Inc.’s financial statements.

  • What is the Inhibikase Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -73.0475355086, which equates to approximately -7,304.75%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Inhibikase Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Inhibikase Therapeutics, Inc.'s financials relevant news, and technical analysis. Inhibikase Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Inhibikase Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Inhibikase Therapeutics, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.